Skip to main content

Table 2 Treatment course and toxicities among patients with relapsed/refractory lymphoma receiving modified EPIC salvage chemotherapy in Lilongwe

From: Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi

  Total (n = 21) HIV+ (n = 13) HIV- (n = 8)
Cycles per patient 3 (1–6) 3 (1–6) 3.5 (1–6)
Days between cycles 28 (25–45) 28 (25–42) 28 (25–45)
Etoposide dose per cycle, mg/m2 100 (48–104) 99 (51–104) 100 (48–102)
Ifosfamide dose per cycle, mg/m2 1000 (482–1042) 993 (511–1042) 1000 (482–1019)
Received >50% of day 15 cisplatin doses, n (%) 2 (10%) 1 (8%) 1 (13%)
Received <4 cycles, n (%) 12 (57%) 8 (62%) 4 (50%)
 Progression 11 7 4
 Social 1 1
Any grade 3/4 neutropenia, n (%) 19 (90%) 11 (86%) 8 (100%)
Any grade 3/4 anemia, n (%) 10 (48%) 4 (31%) 6 (75%)
Any grade 3/4 thrombocytopenia, n (%) 3 (14%) 1 (8%) 2 (25%)
Any grade 3/4 renal dysfunction, n (%) 1 (5%) 1 (8%)
Any grade 3/4 other non-hematologic toxicity, n (%) 8 (38%) 4 (31%) 4 (50%)
  1. Values indicate median (range) unless otherwise specified